139 related articles for article (PubMed ID: 10354916)
1. [S-100 beta protein in serum, a tumor marker in malignant melanoma-- current state of knowledge and clinical experience].
Jäckel A; Deichmann M; Waldmann V; Bock M; Näher H
Hautarzt; 1999 Apr; 50(4):250-6. PubMed ID: 10354916
[TBL] [Abstract][Full Text] [Related]
2. Serum S100--a marker for disease monitoring in metastatic melanoma.
Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
[TBL] [Abstract][Full Text] [Related]
3. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
Schultz ES; Diepgen TL; Von Den Driesch P
Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
6. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
[TBL] [Abstract][Full Text] [Related]
7. S100 protein serum levels in cutaneous malignant melanoma.
Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
[TBL] [Abstract][Full Text] [Related]
10. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum S100 in metastatic malignant melanoma.
Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
[TBL] [Abstract][Full Text] [Related]
12. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
Schlagenhauff B; Schittek B; Ellwanger U; Stroebel W; Blum A; Schwarz M; Rassner G; Garbe C
Melanoma Res; 2000 Oct; 10(5):451-9. PubMed ID: 11095406
[TBL] [Abstract][Full Text] [Related]
13. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2003 Dec; 13(6):587-93. PubMed ID: 14646622
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma.
von Schoultz E; Hansson LO; Djureen E; Hansson J; Kärnell R; Nilsson B; Stigbrand T; Ringborg U
Melanoma Res; 1996 Apr; 6(2):133-7. PubMed ID: 8791271
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
[TBL] [Abstract][Full Text] [Related]
17. [Serum markers for melanoma].
Ugurel S
Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma.
Curry BJ; Farrelly M; Hersey P
Melanoma Res; 1999 Dec; 9(6):557-67. PubMed ID: 10661766
[TBL] [Abstract][Full Text] [Related]
19. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
Jury CS; McAllister EJ; MacKie RM
Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
[TBL] [Abstract][Full Text] [Related]
20. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
